A
Anna Maria Baldelli
Publications - 45
Citations - 1788
Anna Maria Baldelli is an academic researcher. The author has contributed to research in topics: Colorectal cancer & Cancer. The author has an hindex of 19, co-authored 45 publications receiving 1705 citations.
Papers
More filters
Journal ArticleDOI
Neuroprotective Effect of Reduced Glutathione on Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial
Stefano Cascinu,Vincenzo Catalano,Luigi Cordella,Roberto Labianca,Paolo Giordani,Anna Maria Baldelli,Giordano D. Beretta,Emilio Ubiali,Giuseppina Catalano +8 more
TL;DR: Evidence is provided that GSH is a promising drug for the prevention of oxaliplatin-induced neuropathy, and that it does not reduce the clinical activity of oxaloplatin.
Journal Article
Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer.
Stefano Cascinu,Maria Pia Staccioli,Giampietro Gasparini,Paolo Giordani,Vincenzo Catalano,Roberto Ghiselli,Cristina Rossi,Anna Maria Baldelli,Francesco Graziano,Vittorio Saba,Pietro Muretto,Giuseppina Catalano +11 more
TL;DR: VEGF may be used in a clinical setting to identify patients at high risk for relapse who may benefit from adjuvant treatment including new therapeutic strategies such as monoclonal antibody neutralizing VEGF.
Journal ArticleDOI
Mucinous Histology Predicts for Poor Response Rate and Overall Survival of Patients With Colorectal Cancer and Treated With First-Line Oxaliplatin- And/or Irinotecan-Based Chemotherapy
Vincenzo Catalano,Fotios Loupakis,Francesco Graziano,U. Torresi,R. Bisonni,D. Mari,Lorenzo Fornaro,Anna Maria Baldelli,Paolo Giordani,David Rossi,Paolo Alessandroni,Lucio Giustini,R. R. Silva,Alfredo Falcone,S. Demidio,S. L. Fedeli +15 more
TL;DR: It is shown that patients with mucinous colorectal cancer have poor responsiveness to oxaliplatin/irinotecan-based first-line combination chemotherapy and an unfavourable prognosis compared with non-mucinous colorean cancer patients.
Journal ArticleDOI
Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients
Francesco Graziano,R. Bisonni,Vincenzo Catalano,R. R. Silva,S Rovidati,E Mencarini,B. Ferraro,Franco Canestrari,Anna Maria Baldelli,A. De Gaetano,Paolo Giordani,E. Testa,Vittorio Lai +12 more
TL;DR: In selected patients, levocarnitine supplementation may be effective in alleviating chemotherapy-induced fatigue, and this compound deserves further investigations in a randomised, placebo-controlled study.
Journal ArticleDOI
Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
Vincenzo Catalano,Francesco Graziano,Daniele Santini,S. Demidio,Anna Maria Baldelli,David Rossi,Bruno Vincenzi,Paolo Giordani,Paolo Alessandroni,E. Testa,Giuseppe Tonini,Giuseppina Catalano +11 more
TL;DR: The influence of clinico-pathologic factors on the survival of 175 advanced gastric cancer patients, who received second-line chemotherapy at three oncology departments, is evaluated.